Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm
Background. COVID-19 disease is the cause of daily morbidity and mortality worldwide due to its high transmissibility and pathogenicity. To date, intravenous immunoglobulin (IVIg) injection has been used as one of the various treatments for this disease. This study aimed to determine the effect of IVIg injection on the treatment of patients with Coronavirus-induced cytokine storm. Methods. A total of 174 patients with COVID-19 were included in this study based on their clinical characteristics and laboratory findings and were divided into two groups of IVIg recipients and non-recipients according to the treatment they received. Statistical analysis was performed using SPSS version 22.0. A p-value less than 0.05 was considered statistically significant. Results. IVIg was used to treat merely 20 patients and Kaletra and hemoperfusion drugs were used more among IVIg recipient patients (P=0.003 and P=0.001, respectively). COVID-19-positive PCR tests were significantly more frequent among IVIg recipients (P=0.026). The polymorphonuclear neutrophil (PMN) count (P=0.007) and sodium level (P=0.007) were significantly higher in the IVIg recipient group on the first admission day. Moreover, INR levels in the IVIg recipient group were significantly lower on the seventh admission day (P=0.020). The median of total intensive care unit (ICU) duration of hospitalization among IVIg recipients was significantly higher (P=0.001). Conclusion. It seems that the use of IVIg in COVID-19 patients should be further investigated. Practical Implications. IVIg injection could decrease mortality and slightly increase the survival rate among COVID-19 patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
مجله پزشکی دانشگاه علوم پزشکی تبریز - 44(2022), 5, Seite 403-415 |
| Sprache: |
Persisch |
|---|
| Beteiligte Personen: |
Farahnoosh Farnood [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Coronavirus |
|---|
| doi: |
10.34172/mj.2022.045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ000309974 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ000309974 | ||
| 003 | DE-627 | ||
| 005 | 20230526104002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||per c | ||
| 024 | 7 | |a 10.34172/mj.2022.045 |2 doi | |
| 035 | |a (DE-627)DOAJ000309974 | ||
| 035 | |a (DE-599)DOAJ49513c224cfd49e79dd1f72d5a3ba813 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a per | ||
| 100 | 0 | |a Farahnoosh Farnood |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background. COVID-19 disease is the cause of daily morbidity and mortality worldwide due to its high transmissibility and pathogenicity. To date, intravenous immunoglobulin (IVIg) injection has been used as one of the various treatments for this disease. This study aimed to determine the effect of IVIg injection on the treatment of patients with Coronavirus-induced cytokine storm. Methods. A total of 174 patients with COVID-19 were included in this study based on their clinical characteristics and laboratory findings and were divided into two groups of IVIg recipients and non-recipients according to the treatment they received. Statistical analysis was performed using SPSS version 22.0. A p-value less than 0.05 was considered statistically significant. Results. IVIg was used to treat merely 20 patients and Kaletra and hemoperfusion drugs were used more among IVIg recipient patients (P=0.003 and P=0.001, respectively). COVID-19-positive PCR tests were significantly more frequent among IVIg recipients (P=0.026). The polymorphonuclear neutrophil (PMN) count (P=0.007) and sodium level (P=0.007) were significantly higher in the IVIg recipient group on the first admission day. Moreover, INR levels in the IVIg recipient group were significantly lower on the seventh admission day (P=0.020). The median of total intensive care unit (ICU) duration of hospitalization among IVIg recipients was significantly higher (P=0.001). Conclusion. It seems that the use of IVIg in COVID-19 patients should be further investigated. Practical Implications. IVIg injection could decrease mortality and slightly increase the survival rate among COVID-19 patients. | ||
| 650 | 4 | |a intravenous immunoglobulin (ivig) | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a immunoglobulin g (igg) | |
| 650 | 4 | |a covid-19 | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Hamed Valizadeh |e verfasserin |4 aut | |
| 700 | 0 | |a Khalil Ansarin |e verfasserin |4 aut | |
| 700 | 0 | |a Sepideh Zununi Vahed |e verfasserin |4 aut | |
| 700 | 0 | |a Seyyed Sina Hejazian |e verfasserin |4 aut | |
| 700 | 0 | |a Armin Sadeghi |e verfasserin |4 aut | |
| 700 | 0 | |a Leila Namvar |e verfasserin |4 aut | |
| 700 | 0 | |a Farid Rashidi |e verfasserin |4 aut | |
| 700 | 0 | |a Seyyedeh Mina Hejazian |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammadreza Ardalan |e verfasserin |4 aut | |
| 700 | 0 | |a Akbar Sharifi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t مجله پزشکی دانشگاه علوم پزشکی تبریز |d Tabriz University of Medical Sciences, 2022 |g 44(2022), 5, Seite 403-415 |w (DE-627)DOAJ078598397 |x 2783204X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2022 |g number:5 |g pages:403-415 |
| 856 | 4 | 0 | |u https://doi.org/10.34172/mj.2022.045 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/49513c224cfd49e79dd1f72d5a3ba813 |z kostenfrei |
| 856 | 4 | 0 | |u https://mj.tbzmed.ac.ir/PDF/mj-44-403.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2783-2031 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2783-204X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2022 |e 5 |h 403-415 | ||